1.24
7.82%
+0.0899
Predictive Oncology Inc stock is currently priced at $1.24, with a 24-hour trading volume of 41,885.
It has seen a +7.82% increased in the last 24 hours and a -52.49% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.24 pivot point. If it approaches the $1.32 resistance level, significant changes may occur.
Predictive Oncology Inc Stock (POAI) Financials Data
Predictive Oncology Inc (POAI) Revenue 2024
POAI reported a revenue (TTM) of $1.78 million for the quarter ending December 31, 2023, a +18.24% rise year-over-year.
Predictive Oncology Inc (POAI) Net Income 2024
POAI net income (TTM) was -$13.98 million for the quarter ending December 31, 2023, a +45.67% increase year-over-year.
Predictive Oncology Inc (POAI) Cash Flow 2024
POAI recorded a free cash flow (TTM) of -$13.49 million for the quarter ending December 31, 2023, a -5.02% decrease year-over-year.
Predictive Oncology Inc (POAI) Earnings per Share 2024
POAI earnings per share (TTM) was -$3.47 for the quarter ending December 31, 2023, a +50.29% growth year-over-year.
Predictive Oncology Inc Stock (POAI) Latest News
Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Predictive Oncology to Participate in Upcoming San Francisco Conferences
GlobeNewswire Inc.
Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital
GlobeNewswire Inc.
About Predictive Oncology Inc
Predictive Oncology Inc. operates as a science-driven company on the edge of oncology drug discovery. It provides a suite of solutions for the biopharma industry. It offers drug response prediction services leveraging a collection of tumor samples, categorized by tumor type, and powered by artificial intelligence to assist biopharmaceutical companies in the development of new oncology drugs. The company also develops tumor-specific in vitro models for oncology drug discovery and research, as well as offers contract services and research that focuses on solubility improvements, stability studies, and protein production. In addition, it produces and sells STREAMWAY System, a wall-mounted automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Cap:
|
Volume (24h):